Signaturefd LLC lessened its stake in Fresenius Medical Care AG (NYSE:FMS – Free Report) by 27.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 6,341 shares of the company’s stock after selling 2,372 shares during the quarter. Signaturefd LLC’s holdings in Fresenius Medical Care were worth $135,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the company. Castleview Partners LLC boosted its holdings in shares of Fresenius Medical Care by 35.9% in the 3rd quarter. Castleview Partners LLC now owns 17,286 shares of the company’s stock valued at $368,000 after buying an additional 4,571 shares in the last quarter. Blue Trust Inc. boosted its stake in Fresenius Medical Care by 1,060.9% in the third quarter. Blue Trust Inc. now owns 12,863 shares of the company’s stock valued at $274,000 after acquiring an additional 11,755 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in Fresenius Medical Care in the third quarter worth $112,000. GAMMA Investing LLC increased its position in shares of Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after purchasing an additional 1,675 shares in the last quarter. Finally, Kimelman & Baird LLC purchased a new stake in shares of Fresenius Medical Care during the 2nd quarter valued at $186,000. 8.25% of the stock is currently owned by institutional investors.
Fresenius Medical Care Price Performance
Shares of FMS opened at $20.93 on Monday. The firm has a market capitalization of $12.28 billion, a PE ratio of 21.58, a price-to-earnings-growth ratio of 1.11 and a beta of 0.91. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The company’s fifty day moving average price is $20.24 and its 200-day moving average price is $20.15. Fresenius Medical Care AG has a 1-year low of $16.37 and a 1-year high of $22.76.
Wall Street Analysts Forecast Growth
FMS has been the topic of several research analyst reports. Truist Financial boosted their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. StockNews.com initiated coverage on Fresenius Medical Care in a research note on Tuesday, October 8th. They set a “strong-buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.00.
View Our Latest Analysis on FMS
Fresenius Medical Care Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Read More
- Five stocks we like better than Fresenius Medical Care
- What is Insider Trading? What You Can Learn from Insider Trading
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Using the MarketBeat Stock Split Calculator
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG (NYSE:FMS – Free Report).
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.